iRadimed (NASDAQ:IRMD) Releases Earnings Results, Beats Estimates By $0.05 EPS

iRadimed (NASDAQ:IRMD) issued its quarterly earnings data on Tuesday. The medical equipment provider reported $0.54 EPS for the quarter, topping analysts’ consensus estimates of $0.49 by $0.05, FiscalAI reports. iRadimed had a net margin of 26.82% and a return on equity of 23.85%. The business had revenue of $22.69 million during the quarter, compared to analysts’ expectations of $21.60 million. iRadimed updated its Q1 2026 guidance to 0.440-0.480 EPS and its FY 2026 guidance to 2.060-2.210 EPS.

Here are the key takeaways from iRadimed’s conference call:

• IRadimed posted its 18th consecutive quarter of record revenue—Q4 revenue of $22.7M (+17% YoY) and FY2025 revenue of $83.8M (+14%) with GAAP diluted EPS up 25% in Q4 and gross margins around 75–77%.
• Management expects the new 3870 MR IV pump to raise deal ASPs by 10–14% and drive a large replacement wave (targeting an additional ~1,000 domestic channel replacements/year), with a goal of selling north of 2,000 3870 channels domestically and approaching a $50M pump run rate (and a company run rate >$100M when add-ons are included).
• Early pilot feedback has been “very positive” after a December shipment of 23 systems, additional orders are on the books, and a broader sales release begins in April with initial shipments of ~100–130 3870 channels and expected booking ramp in H2 2026.
• Management expects gross margins to be roughly in line in H1 2026 with potential improvement in H2 as higher volumes and ASPs scale, while noting a transitional subscale period and active management of 3860 inventory as the company shifts to 3870 production.
• The balance sheet supports execution—year-end cash of $51.2M, FY operating cash flow of $24.9M and non-GAAP free cash flow of $16.5M after capex for a new Orlando facility.

iRadimed Stock Performance

Shares of NASDAQ IRMD traded down $0.15 during trading on Thursday, reaching $102.93. The company had a trading volume of 4,647 shares, compared to its average volume of 76,275. The stock has a market cap of $1.31 billion, a PE ratio of 58.76 and a beta of 1.11. iRadimed has a 52 week low of $47.48 and a 52 week high of $107.90. The business’s 50 day moving average price is $98.28 and its 200-day moving average price is $83.57.

iRadimed Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Monday, February 23rd will be issued a dividend of $0.20 per share. The ex-dividend date of this dividend is Monday, February 23rd. This is a positive change from iRadimed’s previous quarterly dividend of $0.17. This represents a $0.80 annualized dividend and a dividend yield of 0.8%. iRadimed’s dividend payout ratio (DPR) is 38.86%.

Insider Transactions at iRadimed

In related news, CFO John Glenn sold 15,000 shares of the business’s stock in a transaction that occurred on Thursday, December 11th. The stock was sold at an average price of $97.29, for a total value of $1,459,350.00. Following the completion of the sale, the chief financial officer directly owned 7,362 shares in the company, valued at approximately $716,248.98. The trade was a 67.08% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Roger E. Susi sold 5,000 shares of the company’s stock in a transaction that occurred on Monday, January 26th. The shares were sold at an average price of $100.65, for a total value of $503,250.00. Following the completion of the transaction, the chief executive officer directly owned 2,262,500 shares of the company’s stock, valued at $227,720,625. This represents a 0.22% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 55,000 shares of company stock valued at $5,287,900. Company insiders own 36.80% of the company’s stock.

Hedge Funds Weigh In On iRadimed

A number of hedge funds have recently bought and sold shares of the company. Quarry LP bought a new stake in iRadimed in the third quarter worth about $40,000. Tower Research Capital LLC TRC lifted its position in shares of iRadimed by 191.1% during the 2nd quarter. Tower Research Capital LLC TRC now owns 754 shares of the medical equipment provider’s stock valued at $45,000 after buying an additional 495 shares during the last quarter. Virtus Advisers LLC bought a new position in shares of iRadimed during the 3rd quarter worth $117,000. Aquatic Capital Management LLC raised its position in shares of iRadimed by 210,400.0% in the third quarter. Aquatic Capital Management LLC now owns 2,105 shares of the medical equipment provider’s stock valued at $150,000 after purchasing an additional 2,104 shares during the period. Finally, Quantbot Technologies LP purchased a new stake in shares of iRadimed during the 3rd quarter valued at approximately $164,000. 92.34% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the company. Weiss Ratings reissued a “buy (b-)” rating on shares of iRadimed in a research report on Monday, December 29th. Roth Mkm reiterated a “buy” rating and set a $120.00 price target on shares of iRadimed in a report on Tuesday. Wall Street Zen lowered shares of iRadimed from a “strong-buy” rating to a “buy” rating in a research report on Sunday, October 26th. Lake Street Capital reaffirmed a “buy” rating and set a $120.00 target price on shares of iRadimed in a research note on Wednesday. Finally, Zacks Research raised iRadimed to a “hold” rating in a research note on Tuesday, November 4th. Three analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $120.00.

About iRadimed

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.